Abstract

Daniel Teasley has worked at Merck for over 6 years, serving in product management and product strategy roles across multiple portfolios including custom cell line engineering services, regenerative medicine products for research, cell therapy manufacturing, and viral gene therapy manufacturing. For the past three years, he has been a Senior Product Manager responsible for the development, launch, and marketing of products and services that enable at-scale viral vector manufacturing. He also supports cross-business strategic initiatives in novel modality manufacturing. Dr. Teasley holds a PhD in Molecular Genetics and Genomics from Washington University in St. Louis and a BS in Biology from the College of William and Mary.Katherine (Katie) Schewe has worked at Merck for over 4 years in various roles from product management in Viral & Gene Therapy to quality assurance of Active Pharmaceutical Ingredient manufacturing. Katie holds a MS in Chemistry from Indiana University Purdue University – Indianapolis and a BS in Chemistry from Southern Illinois University – Edwardsville.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call